There were 1,256 press releases posted in the last 24 hours and 429,755 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image